

Puma Biotechnology

Earnings Call

Commercial Update




February 28, 2019

nerlynx™
(neratinib) tablets

Forward-Looking Safe Harbor Statement


This presentation contains forward-looking statements, including statements regarding the timing of expected reimbursement and coverage decisions and regulatory approvals for NERLYNX. All statements other than historical facts are forward-looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. (“Puma”). Forward-looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These risk and uncertainties are identified in Puma’s Annual Report on Form 10-K for the year ended December 31, 2018 and any subsequent documents Puma files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma’s views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.

Puma's Pharmacy and Distributor Network




\$200.5 M in Net Revenue in 2018

16% growth from Q3 to Q4 - 2018



Bottles Sold By Quarter

12% growth from Q3 to Q4 - 2018



- *SP = Specialty Pharmacy Network, SD = Specialty Distributor Network*

Anti-Diarrheal Voucher Program

Launched in Q3 2018



PumaPatientlynx™
Supportive Care
Voucher Program

**FREE 3-MONTH
Anti-Diarrheal Products**

BIN: 610020 **GROUP:** 99992591
ID: XXXXXXXXXXXX

Instructions


1. Present this voucher with a valid prescription at your local retail pharmacy to receive up to a 3-month max benefit per product.
2. Eligible patients will receive their medication at no cost with a valid prescription. For eligibility requirements, see reverse.
3. If you have any questions, please call 1-855-391-0162 for more information.

**Free for Eligible
Patients**

Anti-Diarrheal Products


- Loperamide
- Colestipol
- Budesonide

Time to First Dispense in Specialty Pharmacy Network







74% of patients receive their first dispense within 15 days of a network SP receiving the RX

68% of Targeted Prescribers Reached



- *Reach defined as physician detailed.*
- *Numbers reported for historical quarters may be slightly different from previous statements due to data updates*

Rest of World Partnerships – Timelines

Region	Partner	Expected Regulatory Approval
Australia	 Specialised Therapeutics	<ul style="list-style-type: none"> • 1H 2019
Israel	 MEDISON <small>Delivering Innovative Healthcare</small>	<ul style="list-style-type: none"> • 1H 2019
Canada	 Knight	<ul style="list-style-type: none"> • 2H 2019
Greater China	 CANbridge 北 海 康 成	<ul style="list-style-type: none"> • 1H 2020 – China • 1H 2020 – Hong Kong • 1H 2020 – Taiwan
Latin America South America	 PINT PHARMA	<ul style="list-style-type: none"> • 2H 2019 – Mexico • 1H 2020 – Argentina • 1H 2020 – Chile • 1H 2020 – Ecuador • 1H 2020 – Peru • 2H 2020 – Colombia • 1H 2021 – Brazil

Puma Biotechnology

Earnings Call

Commercial Update



February 28, 2019

nerlynx™
(neratinib) tablets